Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control - OXT_fMRT

Rheinisch-Westfälisch Technische Hochschule Aachen0 个研究点开始时间: 2010年2月22日最近更新: 2013年12月23日

适应症

试验速览

暂无简介。

•Age between 18 and 45,
•Full capacity to understand and execute instructions of the study,
•For patients: diagnosis of social phobia according to ICD-10 using a minimal score of 19 in the Social Phobia Inventory (SPIN, patient assessment) and 55 points in the Liebowitz Anxiety Scale (LAS, assessment by interviewer)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Sinistrality
•Neurological or Somatic illness affecting the cerebral function (e.g. Parkinsons Disease, Epilepsy, Multiple Sclerosis, Brain Tumor)
•Psychiatric disorder according to ICD-10-WHO F0-F3, F8
•Psychiatric disorder according to ICD-10-WHO F (applicable in patients only in untreated or if acute occurrence in the last six months
•Exclusion criteria of MRI (incorporated metal)
•Positive drug test
•Consumption of centrally acting substances
•persons commited governmental or legaly to an institution
•Additionally in women: current of former pregnancy,

发起方

Rheinisch-Westfälisch Technische Hochschule Aachen